Dossier
biopharma
Coverage of biopharma in the Nexus archive.
- STAT+: A former AI regulator, now in industry, says biopharma is reading FDA’s guidance wrong
Tala Fakhouri, who previously worked at the FDA on AI policy, now at Parexel, criticizes the biopharma industry for misinterpreting the FDA's flexible guidance in conservative ways to avoid risk. The article highlights concerns about how industry implementation diverges from the FDA's intended approach.
- Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO
Avalyn Pharma Inc., a biopharma company developing inhaled treatments for rare lung diseases, raised $300 million in a US initial public offering that priced at the top of its marketed range. The stock surged 44% on its first day of trading, with CEO Lyn Baranowski ringing the opening bell at Nasdaq MarketSite in New York.